Commissioning, Qualification & Validation Engineer

Evotec stock holds near 52-week low as new T-cell alliance meets weak earnings. Published on 09/04/2026 at 08:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Evotec stock is trading just above its 52-week low, even after a fresh T-cell research alliance with Plectonic. Investors are weighing the collaboration against sharply lower second-quarter revenue and a projected operating loss for 2026. Evotec (ISIN DE0005664809) stock is trading close to its 52-week low, with shares at 3.25 EUR on Xetra as of September 4, 2026, even after the company announced a new T-cell research alliance targeting solid tumors according to an article on ad-hoc-news.de. New T-cell alliance with limited near-term cash impact. Evotec, the Hamburg-based drug discovery group, has entered a collaboration with biotech partner Plectonic Biotech to develop a novel T-cell engager approach for solid tumors, pairing Evotec's BiTco platform with Plectonic's LOGIBODY technology as reported by ad-hoc-news.de. According to the same report, the Plectonic agreement is the third partnership announced within weeks, following collaborations with Odyssey Therapeutics in autoimmune and inflammatory diseases and a preclinical development mandate from Niagen Bioscience for its NB4168 candidate, highlighting that Evotec's platforms remain attractive to biotech partners despite a challenging share price. Second-quarter figures show a sharp downturn. Fundamentals remain the key concern for investors. Evotec's latest quarterly figures for the three months to June 30, 2026 (second quarter 2026) show revenue of 143.5 million EUR for the April to June period, with first-half 2026 sales at about 300.1 million EUR, representing a 19.2 percent decline year on year according to ad-hoc-news.de. A detailed market overview from finanzen.ch confirms that in the quarter ended June 30, 2026, Evotec generated 143.48 million EUR of revenue, down 16.21 percent compared with 171.24 million EUR in the prior-year quarter, while loss per share widened to -0.26 EUR from -0.24 EUR a year earlier. In addition, adjusted EBITDA swung to a loss of 42.7 million EUR in the first half of 2026 according to the ad-hoc-news.de analysis, underscoring that profitability pressures have intensified even as the company continues to sign new collaborations. Guidance points to a full-year operating loss. The same ad-hoc-news.de article notes that Evotec's management has reaffirmed significantly reduced full-year guidance issued in July 2026, continuing to project an operating loss of up to 105 million EUR for fiscal year 2026, signaling that the current year is expected to remain loss-making despite the pipeline of partnerships. Analyst sentiment has weakened in response. According to the ad-hoc-news.de report, one financial portal cut its average price target for Evotec stock to 4.60 EUR from 5.67 EUR in late August 2026, lowering expectations by more than 1.00 EUR and reflecting a more cautious view of the company's ability to translate its platform deals into earnings. More data and background on Evotec. For additional regulatory filings, historical performance and long-term charts of Evotec, investors can consult the broader company topic pages and official disclosures. Stock near MDAX and TecDAX low despite bounce. Market data compiled by finanzen.ch shows that on September 3, 2026, Evotec shares gained 0.5 percent around midday to 3.32 EUR on Xetra, after opening the session at 3.31 EUR and reaching an intraday high of 3.37 EUR, with about 136,747 shares traded, placing the stock among the stronger names in the MDAX at that point. The same finanzen.ch overview states that Evotec, a TecDAX constituent, hit its lowest level in 52 weeks at 3.12 EUR on September 2, 2026, while the 52-week high of 7.30 EUR was recorded on October 27, 2025, meaning the current price is more than 50 percent below the peak and within about 6.2 percent of the recent low. According to the ad-hoc-news.de article, Evotec shares now trade at 3.25 EUR, only 3.6 percent above a 52-week low of 3.14 EUR set on September 2, 2026, and roughly 57 percent below a 52-week high of 7.75 EUR reached on November 5, 2025, highlighting how sharply valuation has compressed over the past year. Business model: discovery platforms and milestone potential. Evotec's business model centers on deploying its discovery and development platforms, such as the BiTco technology, to secure collaborations that can generate upfront payments, research funding, milestones and potential royalties over time according to the ad-hoc-news.de analysis. The recent sequence of deals with Plectonic, Odyssey Therapeutics and Niagen Bioscience illustrates that the company is actively leveraging its platforms across oncology, autoimmune and inflammatory indications, although both the ad-hoc-news.de report and the finanzen.ch earnings summary emphasize that near-term financial benefits remain limited while losses and revenue declines weigh on results. Evotec stock price level as of early September 2026. For retail investors, the key takeaway is that Evotec stock is currently priced near its technical floor, at 3.25 EUR per share on Xetra as of September 4, 2026 according to ad-hoc-news.de, only a few percent above the recent 52-week low in a TecDAX and MDAX environment that has seen more stable performance from other constituents. Evotec at a glance. * Company: Evotec SE * ISIN: DE0005664809 * WKN: 566480 * Ticker: EVO * Trading venue: Xetra (Germany) * Price (as of September 4, 2026): 3.25 EUR * Market capitalization: 75,200,000 USD (as of September 3, 2026, based on Evotec SE American listing data compiled by StockTitan) * Sector / Industry: Health Care / Biotechnology * Index membership: TecDAX, MDAX Follow Evotec on social platforms. Sponsored Ad Evotec stock: new analysis - 5 September. Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI. en | DE0005664809 | EVOTEC SE | boerse | 70053097 | bgmi

Evotec stock falls again as weak half-year figures and guidance weigh on sentiment. Published on 09/04/2026 at 18:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Evotec stock is sliding further on Xetra, with the biotech group's shares trading close to their 52-week low as of September 4, 2026, after a sharp drop in first-half 2026 revenue and a cut to full-year guidance unsettled investors. Evotec stock (ISIN DE0005664809) is under renewed pressure on Xetra, with the shares changing hands at around 3.22 EUR as of September 4, 2026, down about 1.7 percent in the afternoon session according to finanzen.ch and intraday data from Quotrix. Stock hovers near 52-week low. According to finanzen.ch, Evotec shares were quoted at 3.22 EUR on Xetra at 16:28 as of September 4, 2026, representing a loss of 1.7 percent on the day after opening at 3.27 EUR. Intraday data from Quotrix show parallel trading indications with Evotec at around 3.22 EUR in early dealings, underlining that the stock is currently struggling to gain traction across German trading venues. Weak first-half 2026 figures and cut guidance. The pressure on Evotec stock is closely tied to the company's latest financial figures and guidance. As reported by Boerse Express on September 4, 2026, Evotec recently presented its final numbers for the first half of 2026 and confirmed a lowered full-year outlook. In the second quarter of 2026, revenue fell by 16.2 percent to 143.5 million EUR compared with the same period a year earlier, underscoring the operational strain in the company's core discovery and development services. For the full first half of 2026, Evotec's revenue declined by 19.2 percent year on year to 300.1 million EUR, according to Boerse Express, highlighting that the weakness is not confined to a single quarter but spans the broader period. The earnings picture is also challenging. Adjusted EBITDA for the first half of 2026 came in at minus 42.7 million EUR, marking a clear deterioration from the prior-year profitability and signaling that the business is currently loss-making at the operating level. Management has responded by sharply cutting full-year guidance. For fiscal year 2026, Evotec now forecasts revenue between 570 million and 610 million EUR, down from an earlier range of 700 million to 780 million EUR that had implied continued growth. On the earnings side, the company now expects an adjusted EBITDA loss of between 70 million and 105 million EUR for 2026, whereas previously Evotec had guided to a potential adjusted EBITDA profit of up to 40 million EUR. The shift from a possible profit to a clearly loss-making corridor is a central reason for investors' caution. Boerse Express notes that the stock price moved lower in response to these figures, registering a decline of 2.7 percent over the subsequent week. That reaction suggests that, while some of the downgrade may have been anticipated, the scale of the guidance cut still led to incremental selling. Evotec stock and company figures at a glance. Investors who want to follow Evotec stock more closely can find a compact overview of current price data and past articles via the ISIN, while Evotec's own investor relations materials provide the detailed financials behind the latest guidance changes. Distance to yearly highs and TecDAX environment. The weak guidance and declining earnings also show up clearly in Evotec's longer-term share performance. Boerse Express points out that Evotec shares recently touched a 52-week low of 3.14 EUR on September 2, 2026, leaving the current level of around 3.22 EUR only about 2.5 percent above that low. By contrast, the stock's high for the current period is much higher. Evotec reached a recent year high of 7.75 EUR on November 5, 2025, and the current price is approximately 58 percent below that mark, illustrating just how much market confidence has eroded over the past months. Evotec is part of the German TecDAX index, which groups technology and biotech names listed in Germany. In that environment, the pronounced drop in Evotec stock stands out, as some peers have shown more resilient price behavior while Evotec continues to trade close to its technical floor. For investors, the combination of a nearly 20 percent revenue decline in the first half of 2026, an operating loss and a guidance corridor pointing to further losses provides a clear explanation for why Evotec stock is underperforming within the TecDAX universe. Representative segment and partnerships. Evotec's business model is built around providing discovery and development services to pharmaceutical and biotech partners, spanning areas such as small molecules, biologics and cell-based therapies. A key segment is its research and development collaborations in oncology and immunology, where the company has built a pipeline of partnered assets. Recent coverage on ad-hoc-news.de has highlighted a new T-cell research alliance targeting solid tumors as an example of Evotec's focus on advanced cell-based therapies. While such partnerships can unlock long-term value, the immediate financial impact depends on milestones and service revenues that have not fully offset the current downturn in other parts of the portfolio. For retail investors, this means that Evotec's product and partnership pipeline remains an important qualitative factor, but the near-term share price is being driven more by the hard numbers of revenue, EBITDA and guidance than by the promise of future projects. Evotec stock price as of September 4, 2026. Across German trading venues, Evotec stock is currently consolidating slightly above its freshly set 52-week low. Based on intraday Xetra data from finanzen.ch, the shares traded at 3.22 EUR at 16:28 on September 4, 2026, down 1.7 percent on the session after starting the day at 3.27 EUR and briefly dipping to 3.19 EUR. That narrow distance to the 52-week low of 3.14 EUR reached on September 2, 2026, and the roughly 58 percent gap to the 7.75 EUR high recorded on November 5, 2025, encapsulate the current risk-reward profile of Evotec stock: the valuation reflects significant caution, while any sustained recovery would likely require a visible turnaround in revenue trends and a path back toward positive adjusted EBITDA. Evotec stock fact box. * Company: Evotec SE * ISIN: DE0005664809 * WKN: 566480 * Ticker: EVT * Trading venue: Xetra * Price (as of September 4, 2026, 16:28): 3.22 EUR * Market capitalization: 560,000,000 EUR (as of September 4, 2026) * Sector / Industry: Biotechnology / Life Sciences * Index membership: TecDAX Sponsored Ad Evotec stock: new analysis - 5 September. Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | DE0005664809 | EVOTEC SE | boerse | 70055542 | bgmi

Evotec and Plectonic enter research collaboration to explore new generation of t-cell-engaging approaches for solid tumors. Sep 02, 2026, 02:04 ET * Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY(R) * BiTco designed to boost T cell activation by engaging a costimulatory signaling pathway * LOGIBODY(R) designed to enhance precision of T cell activation based on multispecific antigen signature HAMBURG, Germany and HALLBERGMOOS, Germany, Sept. 2, 2026 /PRNewswire/ - Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY(R) technology with Evotec's proprietary BiTco platform. Plectonic's LOGIBODY(R) technology engineers DNA-protein therapeutics designed to recognize tumors through a highly specific combination of tumor-associated antigens before engaging T cells. Unlike conventional T cell engagers, LOGIBODY(R) molecules require simultaneous binding to a predefined multi-antigen tumor signature to trigger T cell activation. This logic-gated approach represents a novel drug class aimed at improving treatment precision, reducing activation in healthy tissues and potentially broadening the therapeutic window. Evotec's BiTco platform is based on a proprietary, non-blocking CD2 antibody designed to provide an additional costimulatory signal to T cells, enhancing their activity and persistence within the tumor microenvironment. The antibody targets a unique CD2 epitope while preserving its natural interactions, enabling BiTco to strengthen T cell responses, enhance tumor cell killing mediated by T cell engagers, and delay T cell exhaustion. By combining highly selective tumor recognition and enhanced T-cell activation, the companies will explore whether their integrated technologies can improve both the precision and potency of T-cell-engaging approaches in solid tumors. Under the terms of the agreement, the collaboration will generate preclinical proof-of-concept data to evaluate the potential of this new generation of T-cell-engaging approaches. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said: "T cell engagers have demonstrated significant promise in oncology in blood cancers, yet challenges remain in extending their clinical success to solid tumors, which represent approximately 90 percent of all cancers. Through this collaboration, we aim to evaluate the potential of combining our proprietary BiTco platform with Plectonic's LOGIBODY(R) technology and explore new strategies to enhance T cell engager activity in solid tumors. Our CD2-based co-stimulation approach is an ideal component for this effort or any TCE development strategy that seeks an effective source of T cell co-stimulation in the solid tumor setting." Dr. Klaus Wagenbauer, CEO and Founder of Plectonic Biotech, added: "This collaboration with Evotec highlights the broad potential and modularity of our LOGIBODY(R) technology to engineer logic-gated T-cell-engaging biologics and explore novel multi-specific designs. By combining our complementary technologies, we have the opportunity to enable highly precise and controlled immune activation at the tumor. Together, we look forward to investigating this next-generation modality and exploring new ways to address long-standing challenges in tumor selectivity and safety that have limited the effectiveness of T cell engagers in solid tumor indications." Plectonic has demonstrated the modularity of its LOGIBODY(R) technology in preclinical studies across both liquid and solid tumors, utilizing dual-targeting and co-stimulatory therapeutic strategies. Evotec recently published preclinical research on its BiTco platform, providing proof-of-concept for CD2-mediated T cell co-stimulation in combination with T cell engager approaches. About Plectonic Biotech Plectonic Biotech's new class of programmable DNA-protein therapeutics function as molecular logic gates to selectively direct the immune response to the tumor. By applying our modular LOGIBODY(R) platform, we are building a pipeline of multi-specific T-cell-engaging biologics designed to overcome off-target toxicity and exponentially improve the therapeutic impact of immunotherapies using clinically validated targets. Initially focused on hematologic malignancies, our approach is designed to deliver an unprecedented level of precision and control, broadening the therapeutic window and improving patient outcomes in both liquid and solid tumors. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Evotec Investor Relations and Media Contact Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations [email protected] Plectonic Media Contact Trophic Communications Joe Rayne or Stephanie May [email protected] +49 171 185 5682 SOURCE Evotec SE